Last updated: 2026-09-27 13:32:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Merck & Co., Inc. (MRK) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $148,73, with a market capitalization of $367,07B and a P/E ratio of 115,68. Over the past 52 weeks, its price has ranged from $78,03 to $156,92. This page covers its latest market performance, valuation, price trends and company information.
$367,07B | |
$148,06 | |
$156,92 | |
$15,32 | |
$147,98 | |
6,14M | |
9,93M | |
115,68 | |
$156,92 | |
$78,03 | |
2,26% | |
-- |
Merck & Co., Inc. (MRK) last closed at $147,98 as of 2026-09-26 00:00:00, unchanged from the previous close of $147,98.
During the latest regular trading session, MRK traded between $15,32 and $156,92, with a volume of 6,14M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Merck & Co., Inc. (MRK) moved from $147,15 to $148,73, representing a gain of 1,08% ($1,58).
The stock traded between $145,32 and $153,57 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 12,81 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 89,6%
MRK is currently trading at $148,73, placing it 89,6% of the way from its 52-week low of $78,03 to its 52-week high of $156,92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 75000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Merck & Co., Inc. (MRK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.